OpusPoint Partners are now the trendsetters in the advancement of life science and healthcare. They are on a quest to revolutionize the way in which the newest innovations in healthcare will be delivered to the market. Their vision requires that time and money be invested into companies whose innovations require that extra financial push to make it into the industry.
OpusPoint Partners was founded by visionaries Michael S. Weiss and Dr. Lindsay Rosenwald in 2009 with dreams of improving the levels of healthcare and medicine throughout the world. This was only one of a number of biotech companies founded by these two men who have retained their passion for the world of biotechnology with their combined 40 years worth of experience, investing in the fields of life sciences and biotechnology and ensuring that the future of all mankind is stronger and healthier.
Dr. Lindsay Rosenwald is also accredited with the founding of another company called Cougar Biotechnology Inc. which is Los Angeles based and has an excellent portfolio which includes experimental drugs for cancer which have been impressing researchers and investors worldwide. One of these drugs has received a wealth of attention because of its success in the treatment of prostate cancer that has advanced to the late stages. On July 10, 2009, Johnson and Johnson purchased Cougar Biotech Labs for an estimated one billion dollars.
OpusPoint Partners with Lindsay Rosenwald has been focusing on growing the connections with the investment and biotechnology communities and building these strong business links. Integrity is the hallmark of their operation and this trait is practiced with full and open disclosure and honesty in their investing. They found that when good core values are shared in the establishment of the business the companies and industry leaders develop strong business relationships. Recognition that integrity is not only a good business practice but is intrinsically interwoven into the fabric of the organization’s culture keeps all of the parties grounded and focused.
These business teams are made up of various individuals and corporations as well as investors and researchers with a common mission to help the emerging companies attain their critical business goals and succeeding in providing the world with revolutionary innovations to improve the diagnosis and treatment of many diseases. Collectively with these teams, OpusPoint Partners will continue to make new discoveries in these fields and invest more into research companies that are on the threshold of accomplishing great medical breakthroughs.
Dr. Lindsay Rosenwald and OpusPoint Partners have taken the area of biotech investing to new heights. They are setting the trend by raising the bar for investing and advising biotechnical facilities, by employing a strong set of values and insisting that sound business principles be applied. With these business tools being utilized they believe that investors can be provided with optimal returns, without increased exposure to the risks. This formula has been tested and has proven to be effective.
Dr. Rosenwald is well prepared for the challenges ahead as he has had more than seventeen years experience as a biotechnology entrepreneur on Wall Street. He has kept active in the founding and re-capitalization of private and public companies that are focused on the life sciences and biotech industries. Dr. Rosenwald has both an M.D. form the Temple University School of Medicine as well as a B.S. in Finance from Pennsylvania State University.
For thirteen years from 1994 to 2007 Dr. Rosenwald managed billions of dollars for the Aries Funds which placed more than one billion dollars on healthcare investments and peaked with its assets under his management. He also managed the Orion Fund from 2002 to 2006. The Orion Fund is dedicated to the allocation of private biotechnology investing in particular in PIPEs.
OpusPoint Partners retains its founding principle which is to establish a strong and successful conglomeration that remains committed to honesty and integrity in the areas of life science and healthcare. Business leaders in today’s competitive business environments are pursued by temptations to take the short cuts and compromise their ethics in an effort to produce positive clinical trials to have an impact on their earnings and profits.
OpusPoint Partners has a completely different philosophy. It remains firmly committed to its shareholders made up of investors and employees while still reinforcing fair play in all of its dealings especially when it comes to the testing, investigation and manufacture of drugs.
Change can sometimes be difficult and it will take some work to alter the age-old procedures and techniques in medicine while still remaining within ethical boundaries. Time, money and dedication must be pumped into the projects to avoid the need by the companies to ignore ethics and cross the line of what is right, just to increase the profits.
The future of OpusPoint Partners is promising because of the experienced leadership of Michael Weiss and Dr. Lindsay Rosenwald. As a dual team it is expected that their expertise will be instrumental in the trendsetting modus operandi that improves the areas of medical treatments as well as the diagnosis and treatment of patients.
The successes of OpusPoint are already visible. The company within the last few years has been performing above the initial projected goals and have financed over twenty companies in less than a two year period, proving that the application of best practices and fine-tuned processes have produced promising results and returns in the worlds of finance and drug research.
Dr. Lindsay Rosenwald is on the Board of Directors for the Republican Jewish Coalition which affords him the opportunity to forge close connections to industry leaders in the biotechnology financial sector. OpusPoint Partners are eagerly anticipating a future that is marked by even more successes under its leadership.
